Vidofludimus
货号：
18377-1mg 基本售价：
406.0 元 规格：
1 mg
产品信息
概述| 货号 | 18377-1mg |
| 描述 | Dihydroorotate dehydrogenase (DHODH) is involved in pyrimidine nucleoside biosynthesis. DHODH inhibitors have value in autoimmune diseases as well as cancer and certain infections.1 Vidofludimus is an immunosuppressive drug that inhibits DHODH (IC50s = 0.134, 1.29, and 10.6 µM for human, rat, and mouse isoforms, respectively).2,3 Through this action, it inhibits the proliferation of T cells and B cells and the secretion of IL-17 (IC50s = 12.9, 3.7, and 6.0 µM, respectively, in human cells).2,3 Oral administration of vidofludimus improves both chronic dextran sodium sulfate-induced and acute TNBS-induced colitis in mice.2 |
| 别名 | 4SC-101; |
性能| 供应商 | Cayman |
| 应用文献 |
1.Munier-Lehmann, H.,Vidalain, P.O.,Tangy, F., et al. On dihydroorotate dehydrogenases and their inhibitors and uses. Journal of Medicinal Chemistry 56(8), 3148-3167 (2013).
2.Fitzpatrick, L.R.,Deml, L.,Hoffmann, C., et al. 4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease. Inflamm.Bowel Dis. 16(10), 1763-1777 (2010).
3.Fitzpatrick, L.R. Novel pharmacological approaches for inflammatory bowel disease: Targeting key intracellular pathways and the IL-23/IL-17 axis. Int.J.Inflam. 2012:389404, (2016).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 355.4 |
| 分子式 | C20H18FNO4 |
| CAS号 | 717824-30-1 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
